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Abstract
Background: Liver resection and the use of small-for-size grafts are restricted by the necessity to provide a sufficient
amount of functional liver mass. Only few promising strategies to maximize liver regeneration are available. Apart from its
erythropoiesis-stimulating effect, erythropoietin (EPO) has meanwhile been recognized as mitogenic, tissue-protective, and
anti-apoptotic pleiotropic cytokine. Thus, EPO may support regeneration of hepatic tissue.
Methodology: Rats undergoing 68% hepatectomy received daily either high dose (5000 IU/kg bw iv) or low dose (500 IU/kg
bw iv) recombinant human EPO or equal amounts of physiologic saline. Parameters of liver regeneration and hepatocellular
apoptosis were assessed at 24 h, 48 h and 5 d after resection. In addition, red blood cell count, hematocrit and serum EPO
levels as well as plasma concentrations of TNF-a and IL-6 were evaluated. Further, hepatic Bcl-xL and Bax protein expression
were analyzed by Western blot.
Principal Findings: Administration of EPO significantly reduced the expression of PCNA at 24 h followed by a significant
decrease in restitution of liver mass at day 5 after partial hepatectomy. EPO increased TNF-a levels and shifted the Bcl-xL to
Bax ratio towards the pro-apoptotic Bax resulting in significantly increased hepatocellular apoptosis.
Conclusions: Multiple doses of EPO after partial hepatectomy increase hepatocellular apoptosis and impair liver
regeneration in rats. Thus, careful consideration should be made in pre- and post-operative recombinant human EPO
administration in the setting of liver resection and transplantation.
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Introduction
The liver is one of the most remarkable organs because of its
endogenous property to proliferate and to fully regenerate. The
process of liver regeneration after partial hepatectomy (pHx)
includes the division of almost all hepatocytes with the goal of
replacing the lost functional mass. Meanwhile, large amounts of
information have become available about the underlying mech-
anisms of cell replication [1,2]. It is common view that liver
regeneration encompasses three pathways, i.e. cytokine, growth
factor and metabolic, linking liver function with cell growth and
proliferation [2]. The cytokines, growth factors and metabolic
signals must delicately interact to coordinate gene expression
during the immediate early response. A characteristic feature of
the regenerative process is that all components of each pathway
are required for optimal regeneration, though no single gene,
factor or mediator can be considered mandatory and essential for
liver regeneration [1].
Great advances in the understanding of the regeneration
process encourage hepatologists and transplant surgeons to further
propel living donor liver transplantation and extended liver
resections. Thus, therapeutic strategies are needed, which allow
for promoting growth of ‘small-for-size’ transplants or limited
residual mass [3,4]. In addition, diseased livers with compromised
regeneration, such as cirrhotic or acute necrotic livers, would
benefit from liver growth-enhancing strategies [5]. Within this
context, recombinant human erythropoietin (rHuEPO) treatment
seems to be a valid approach, because the drug is already available
and has a distinct safety margin for human use [6–8]. Besides its
hematopoietic function, EPO has meanwhile been recognized as
an anti-apoptotic, mitogenic and tissue-protective pleiotropic
cytokine [9–11]. Recent studies have identified multiple paracrine
and autocrine functions of EPO and its analogues that coordinate
local responses to injury in brain, kidney and myocardium by
inhibition of apoptosis and augmentation of cellular regeneration
[12–15].
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3924Schmeding et al. demonstrated that portalvenous administra-
tion of EPO increased liver regeneration in rats after 70% liver
resection [16]. However, the same group could not confirm their
own previous observation of EPO on liver regeneration [17]. In
the here presented study, we communicate that multiple doses of
EPO is accompanied by release of TNF-a and delays restoration




Male Sprague-Dawley rats (body weight (bw) 250–350 g;
Charles River Laboratories, Sulzfeld, Germany) were used. The
experiments were conducted in accordance with the German
legislation on protection of animals and the NIH Guide for the
Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, National Research Council). Animals were
housed in standard rooms of the central animal husbandry of our
faculty with a 12 hour light-dark cycle and had free access to water
and standard laboratory chow ad libitum.
For hepatectomy, animals were anesthetized by breathing
isoflurane (1.6 vol%) in air and subjected to a 68% hepatectomy
according to the method described by Higgins and Anderson
[18]. In supine position, an upper midline incision of the
abdomen was followed by retraction of the xyphoid cartilage for
adequate exposure of the liver and division of hepatic ligaments.
The right median, the left median and the left lateral lobes were
ligated and removed, resulting in a 68% hepatectomy. After
irrigation of the abdomen with warm saline, the peritoneum and
the skin were closed with running 6–0 and 5-0 sutures,
respectively. Postoperatively, animals were allowed to recover
from anesthesia and had free access to food and water until the
final experiment.
Experimental groups and protocol
Animals received 5000 IU/kg bw EPO (high dose) intrave-
nously every 24 h starting at 248 h prior to hepatectomy. Animals
which daily received equivalent amounts of physiologic saline
solution served as controls. At either 24 h, 48 h or 5 d after
hepatectomy (n=6–10 animals at each time point and group)
animals were exsanguinated by cardiac puncture under pentobar-
bital anesthesia and blood as well as liver tissue was sampled for
subsequent analysis. Wet weight of regenerated liver was used to
calculate growth of residual liver lobes by the following formula:
weight of regenerated liver/preoperative liver weight6100 (%).
Preoperative liver weight was estimated as 3.75% of body weight
[19].
In an additional set of experiments rats received EPO 500 IU/
kg bw (low dose) intravenously every 24 h starting at 248 h prior
to hepatectomy. At 24 h post hepatectomy, i.e. at maximum of
DNA-synthesis [20], animals (n=4) were killed and blood as well
as liver tissue were sampled as described above. Hepatectomized
animals which daily received equivalent amounts of physiologic
saline solution served as controls (n=4). To study liver cell
proliferation 5-bromo-29-deoxyuridine (BrdU, 50 mg/kg bw) was
applied intraperitoneally 1 h before sacrifice.
For determination of physiological baseline values blood
samples were obtained from non-resected, untreated rats (n=5)
via the tail vein under light isoflurane anesthesia.
Laboratory analysis
Systemic blood cell counts were measured using a Coulter
Counter (AcTdiff, Coulter, Hamburg, Germany). Moreover,
blood samples served for analysis of EPO concentrations using
chemiluminescence enzyme immuno assay (DPC, Bad Nauheim,
Germany). EDTA plasma further served for spectrophotometrical
determination of alanine aminotransferase (ALT) as well as for
analysis of tumor necrosis factor (TNF)-a and interleukin (IL)-6,
using commercially available enzyme-linked immunosorbent assay
(ELISA) kits in accordance to the manufacturer’s instructions
(Pierce Biotechnology, Rockford, IL 61105, USA).
Histology and immunohistochemistry of liver tissue
Remnant liver tissue was excised at 24 h, 48 h and 5 d after
resection, fixed in 4% phosphate-buffered formalin for 2 to 3 days
and then embedded in paraffin. For immunohistochemical
demonstration of PCNA and BrdU, 4 mm sections collected on
poly-L-lysine-coated glass slides were treated by microwave for
antigen unmasking. Mouse monoclonal anti-PCNA (1:100;
Novocastra Laboratories, Newcastle upon Tyne, UK) and mouse
monoclonal anti-BrdU (1:50; Dako Cytomation, Hamburg,
Germany) were used as primary antibodies and incubated for 18
ha t4 uC. After equilibrating to room temperature, sections were
incubated with horseradish peroxidase-conjugated goat anti-
mouse IgG (1:100) for 30 min (Dako Cytomation). Fuchsin
(PCNA) or 3,39-diaminobenzidine (BrdU) were used as chromo-
gens. The sections were counterstained with hemalaun and
examined by light microscopy (Axioskop 40, Zeiss, Go ¨ttingen,
Germany). PCNA- and BrdU-positive nuclei were counted within
40 consecutive high power fields (x40 objective, numerical
aperture 0.65) and are given as positive cells per mm
2. For
quantification of apoptotic cell death, 4 mm sections were mounted
on poly-L-lysine glass slides and exposed to an apoptosis-specific
staining kit (indirect in situ DNA nick end labeling (TUNEL)
assay; ApopTag, Chemicon International, Inc., Temecula, CA,
USA) according to the manufacturer’s instructions. TUNEL-
positive hepatocytes were counted within 40 consecutive high
power fields and given as positive cells per mm
2.
Western Blot analysis
For Western blot analysis of Bcl-xL and Bax, liver tissue was
homogenized in lysis buffer (1 M Tris pH 7.5, 5 M NaCl,
250 mM EDTA, 10% Triton-X 100, 4% NaN3, and 100 mM
PMSF), incubated for 30 min on ice, and centrifuged for 15 min
at 10,0006g. Prior to use, all buffers received a protease inhibitor
cocktail (1:100 vol/vol; Sigma, St. Louis, MO, USA). Protein
concentrations were determined using the BCA protein assay
(Pierce, Rockford, IL, USA) with bovine serum albumin as
standard. Equal amounts of whole protein extracts (20 mg) were
separated discontinuously on sodium dodecyl sulphate polyacryl-
amide gels (12% SDS-PAGE) and transferred to a polyvinyldi-
fluoride membrane (Immobilon-P transfer membrane; Millipore,
Billerica, MA, USA). After blockade of non-specific binding sites,
membranes were incubated for 2 h at room temperature with a
mouse monoclonal anti-Bcl-xL (1:1,000; BD PharMingen,
Heidelberg, Germany) or a mouse monoclonal anti-Bax antibody
(1:250; BD PharMingen), followed by a secondary peroxidase-
linked anti-mouse antibody (BcL-xL 1:10,000 and Bax 1:20,000;
Sigma). Protein expression was visualized by means of luminol
enhanced chemiluminescence (ECL plus, Amersham Pharmacia
Biotech, Freiburg, Germany) and digitized with ChemiDoc
TM
XRS System (Quantity One, Bio-Rad Laboratories GmbH,
Munich, Germany). Signals were densitometrically assessed
(Quantity One) and normalized to the b-actin signals as loading
controls (mouse monoclonal anti-b-actin antibody, 1:20,000;
Sigma).
EPO and Liver Regeneration
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Data are expressed as means6SEM. The Kolmogorov-Smirnov
test was applied for analyzing the normality of the distribution of
the parameters. The unpaired Students t-test was used to compare
mean values between groups at the respective time point. The
parameters that did not fit into normal distribution were compared
using the Mann-Whitney rank sum test. Differences were
considered statistically significant when P,0.05 (SigmaStat, Jandel
Corporation, San Rafael, CA, USA).
Results
Systemic effects upon EPO administration
Daily administration of high dose EPO (5000 IU/kg bw) caused
a massive rise of circulating EPO concentrations with a maximum
value of almost 2500 mU/mL at 24 h after resection, while EPO
was barely detectable in controls (table 1). EPO stimulated
hematopoiesis in a time-dependent fashion with an increased
hematocrit of 59% at 5 d after hepatectomy and an increased red
blood cell (RBC) count of 9.3610
12/L compared to normal values
of 40–45% and 6.9–7.5610
12/L in saline-treated controls (table 1).
In contrast, administration of low dose EPO (500 IU/kg bw) led to
an only slight increase of the hematocrit (47%) and the RBC count
was not different compared to that measured in control animals
(table 1).
Effect of high dose EPO on hepatocellular proliferation
To evaluate the influence of EPO on the regenerative capacity
after pHx, livers were studied by immunohistochemistry for
hepatocellular proliferation at 24 h, 48 h and 5 d after resection.
PCNA labeling revealed a significant inhibition of hepatocellular
proliferation in EPO-treated animals in particular during the
initial 24-h-period after liver resection (figure 1A). As a
consequence, restoration of liver weight after EPO administration
was markedly delayed (figure 1B). Whereas control animals
revealed a constant increase of liver mass upon pHx achieving
,80% of preoperative liver weight at day 5 after resection, EPO-
treated animals showed only a limited restoration up to ,65% of
the initial liver weight at day 5. This strongly underscores the
deteriorating effect of high dose EPO on the process of liver
regeneration.
Effect of high dose EPO on hepatocellular apoptosis
Western blot analysis showed that EPO administration led to a
higher expression of the anti-apoptotic gene Bcl-xL at 24 h after
hepatectomy when compared with vehicle-treated controls
(figure 2A). However, expression of Bcl-xL decreased at the
following days to equal levels in both groups (figure 2A). EPO-
treated animals further showed a transient rise of the pro-apoptotic
gene Bax at 48 h after hepatectomy, while expression of Bax
remained unchanged in controls (figure 2B). Consequently, EPO-
treated animals revealed a shift of the Bcl-xL/Bax ratio from a net
anti-apoptotic at 24 h towards a net pro-apoptotic effect at 48 h
(figure 2C). In line with this, control and EPO-treated animals
demonstrated completely different patterns of hepatocellular
apoptosis upon pHx (figure 3). Whereas control animals revealed
decreasing numbers of TUNEL-positive hepatocytes from 13/
mm
2 at 24 h to 5/mm
2 at 5 d after liver resection, high dose
administration of EPO resulted in increasing numbers of apoptotic
cells with ,25/mm
2 at day 5 (figure 3).
Effect of high dose EPO on transaminase and cytokine
release
Application of EPO significantly reduced systemic ALT release
at 24 h after pHx compared to saline-treated controls (figure 4A).
Partial hepatectomy was accompanied by a transient release of
TNF-a of about 40 pg/mL at 24 h and 48 h after liver resection in
control animals. At day 5 TNF-a was not anymore detectable. In
contrast, EPO-treated animals revealed steadily increasing plasma
levels of TNF-a from 100 pg/mL at 24 h to 300 pg/mL at day 5
after hepatectomy (figure 4B). Concomitantly, administration of
EPO caused also an elevation of plasma IL-6 concentrations at all
time points studied when compared with resected saline-treated
animals (figure 4C).
Effect of low dose EPO on hepatocellular proliferation
In order to clarify, whether the impairment of liver regeneration
after high dose EPO was induced by its pleiotropic, i.e. non-
hematopoietic actions or just only by the increased hematocrit, an
additional set of animals with administration of low dose EPO (500
IU/kg bw) was analyzed at the time point of maximal DNA
synthesis, i.e. at 24 h after pHx. Analysis of both PCNA expression
and BrdU incorporation revealed a statistically significant
impairment of hepatocellular proliferation and DNA-synthesis in
animals treated with the low dose of EPO when compared to
saline-treated controls (figure 5).
Discussion
The present study communicates the following major findings:
(i) Daily administration of EPO in hepatectomized rats results in
high circulating concentrations of EPO, which time-dependently
induce erythropoiesis. (ii) EPO impairs liver cell proliferation upon
pHx. (iii) EPO upregulates TNF-a and increases apoptotic cell
Table 1. Serum EPO concentration, hematocrit and red blood cell count
baseline 5000 IU/kg bw iv 500 IU/kg bw iv
24 h 48 h 5 d 24 h
Con EPO Con EPO Con EPO Con EPO
serum EPO [mU/mL] 14.967.7 1.060.0 24536167* 1.560.2 8416254* 1.160.4 7266400* 14.767.6 147676*
hematocrit [%] 40.562.5 44.962.4 52.660.6* 45.061.9 55.161.0* 40.161.2 58.662.4* 42.462.5 47.364.1
RBC count [10
12/L] 6.760.4 7.560.3 8.260.1* 7.160.3 8.260.2* 6.960.1 9.360.5* 7.060.4 7.360.7
Serum EPO concentration, hematocrit and red blood cell (RBC) count in animals at 24 h, 48 h and 5 d after pHx and daily administration of EPO at a dose of either 5000
IU/kg bw or 500 IU/kg bw. Control animals received equivalent volumes of physiologic saline (Con). For determination of physiological baseline values blood samples
were obtained from non-resected, untreated rats (baseline). Data are given as means6SEM; Mann-Whitney rank sum test,
* P,0.05 vs Con at the respective time point
and EPO dose.
doi:10.1371/journal.pone.0003924.t001
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pro-apoptotic effect.
Loss of liver cells caused by surgical resection, viral disease or
chemical injury triggers replication of hepatocytes, which are
capable of repopulating the liver. Nonetheless, conditions of
compromised regeneration, such as acute liver failure, small-for-
size transplants and liver cirrhosis, necessitate the development of
therapeutic strategies to obtain rapid growth of the remnant liver.
It has been shown that healthy live-liver donors did not achieve
complete liver regeneration and ultimately reach only approxi-
mately 85% of the mass of the original liver during the first 12
months post-transplantation [3,4,21]. The incomplete or delayed
regeneration of the liver bears the risk of having a reserve capacity
deficit and thus might benefit from growth-supporting regimens.
As production of EPO is generally suppressed following injury,
administration of exogenous EPO seems to be a valid approach in
this context. The observation that cyclosporine-based immuno-
suppression inhibits EPO production after liver transplantation
Figure 1. PCNA expressing hepatocytes and restoration of liver weight. Quantitative analysis of PCNA expressing hepatocytes (A) and
restoration of liver weight (B) in animals at 24 h, 48 h and 5 d after pHx and daily administration of high dose EPO (5000 IU/kg bw iv; closed bars) or
physiologic saline solution (open bars). PCNA expression was assessed by immunohistochemistry. The weight of the regenerating liver was used to
calculate the growth of residual liver lobes. For detailed information please see section Material and Methods. Means6SEM; unpaired Student’s t-test.
*P ,0.05 vs the saline-treated group at the respective time point.
doi:10.1371/journal.pone.0003924.g001
Figure 2. Anti-apoptotic Bcl-xL and pro-apoptotic Bax as well as the Bcl-xL/Bax ratio. Protein expression of anti-apoptotic Bcl-xL (A) and
pro-apoptotic Bax (B) as well as the Bcl-xL/Bax ratio (C) in animals at 24 h, 48 h and 5 d after pHx and daily administration of high dose EPO (5000 IU/
kg bw iv; closed bars) or physiologic saline solution (open bars). Data are normalized to ß-actin as loading control. Means6SEM; unpaired Student’s t-
test. * P,0.05 vs the saline-treated group at the respective time point.
doi:10.1371/journal.pone.0003924.g002
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support.
Herein, we show that administration of EPO delays liver
regeneration after pHx. Daily administration of high dose EPO
(5000 IU/kg bw) in hepatectomized rats reduces the expression of
PCNA and results in a significantly diminished restoration of liver
mass. Also, a ten-fold lower dose of EPO (500 IU/kg bw) led to
decreased PCNA expression and a diminished DNA synthesis at
the timepoint of maximal DNA-synthesis in comparison to animals
without EPO treatment. Being aware that the dose of 5000 IU/kg
bw is a very high one when compared with that used for treatment
of anemia (10–15 IU/kg), one has to consider that similar doses
have been used experimentally to exert cytoprotective effects in
non-hematopoietic cells [23]. Dosing of 5000 IU/kg in rodents is
comparable to the dose of about 500 IU/kg which has been tested
in humans in a small clinical stroke [24], taking into account the
different weight-to-surface ratio. In addition, recombinant human
EPO displayed a 3-4 time extended half-life in humans compared
to controls [25,26]. The observed delay of hepatic regeneration is
in contrast to a most recently published work by Schmeding et al.
showing that administration of rHuEPO effectively increased liver
regeneration in rats after 70% liver resection [16]. The discrepant
results of the latter study and the present one may be related to
differences in the route of EPO administration. Whereas in the
present study EPO was applied daily via the tail vein, Schmeding
and coworkers analyzed two different modalities namely subcu-
taneous and intraportalvenous EPO application, however, dis-
playing identical effects for both study groups [16]. Unfortunately
Figure 3. Hepatocellular apoptosis. Apoptotic cell death, as assessed by TUNEL-analysis in animals at 24 h, 48 h and 5 d after pHx and daily
administration of high dose EPO (5000 IU/kg bw iv; closed bars) or physiologic saline solution (open bars) (A). Representative images at day 5 after
pHx of a saline-treated control (B) and an EPO-treated animal (C). Arrowhead indicate TUNEL-positive apoptotic hepatocytes. Bars represent 50 mm.
Means6SEM; unpaired Student’s t-test. * P,0.05 vs the saline-treated group at the respective time point.
doi:10.1371/journal.pone.0003924.g003
Figure 4. Transaminase and cytokine release. Plasma levels of ALT (A), TNF-a (B), and IL-6 (C) in animals at 24 h, 48 h and 5 d after pHx and daily
administration of high dose EPO (5000 IU/kg bw iv; closed bars) or physiologic saline solution (open bars). Means6SEM; unpaired Student’s t-test. *
P,0.05 vs the saline-treated group at the respective time point.
doi:10.1371/journal.pone.0003924.g004
EPO and Liver Regeneration
PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e3924no data of EPO serum levels and hematocrit were presented.
Schmeding et al. did not show whether the observation of
enhanced regeneration capacity after 70% liver resection resulted
in an increased restoration of liver mass. Moreover, in a most
recently published work of the same group about a synergistic
effect of EPO in combination with curcumin the authors could not
confirm their previous result of EPO on liver regeneration [17].
These conflicting observations suggest caution in the use of EPO
after liver resection.
Herein, we observed a cytoprotective effect of EPO during the
first day after pHx, whereas EPO treatment resulted in a rise of
apoptotic cell death during the late phase of the regeneration
process. It has been shown, that EPO displays its protective effects
in non-hematopoietic tissue by regulating the balance between
pro- and anti-apoptotic Bcl-2 family proteins. Johnson et al.
reported that in acute renal failure EPO decreased the expression
of pro-apoptotic Bax and did not affect the expression of anti-
apoptotic molecules Bcl-2 and Bcl-xL [15]. On the other hand,
EPO increased the expression of Bcl-xL in vitro [7] and the
marked shift in Bcl to Bax ratio was consistent with an overall
antiapoptotic effect of EPO on rat microglial cells [27].
Concomitantly, renoprotective [28] and neuroprotective [29]
effects of EPO could be attributed to an upregulation of Bcl-2
and a downregulation of Bax. Though the relative balance of the
Bax and Bcl-xL proteins seems to be a critical factor, the exact
mechanism responsible for the anti-apoptotic efficacy of EPO is
not yet clarified [30]. In the present study we could observe an
initial upregulation of the anti-apoptotic member Bcl-xL at 24 h
after pHx in the EPO-treated group. However, the Bcl-xL
expression decreased to 50% at 48 h, whereas a concomitant
increase of the pro-apoptotic Bax protein could be deteced. Along
with this shift of the Bcl-xL/Bax ratio towards the pro-apoptotic
Bax at 48 h, massive apoptosis occurred at day 5. To the best of
our knowledge this is the first report of a proapoptotic effect after
repetitive injection of EPO.
Astonishingly, EPO treatment in the setting of liver resection
resulted in an increase of TNF-a, which is in contrast to previous
studies showing that EPO exerts its tissue-protective effect in the
liver through a reduction of the serum levels of several cytokines
[31,32]. It is to note that identical application of EPO in animals
without liver resection did not result in a comparable elevation of
TNF-a plasma levels (own unpublished observations). TNF-a
exerts two paradoxical effects on the process of liver regeneration
[33]. TNF-a released between 1 and 12 hours post hepatectomy
initiates liver regeneration through its receptors located on
hepatocytes and nonparenchymal cells. On the other hand,
excessive TNF-a production between 12 and 24 hours after liver
resection was considered to be a major determinant of liver failure
[33]. TNF-a is mainly produced by Kupffer cells. As LPS is a
potent stimulator of TNF-a release by Kupffer cells it has been
speculated that resection-induced elevation of portal blood flow
with increased load of LPS to the remnant liver provokes the
Kupffer cells to release TNF-a [34]. However, the distinct stimulus
for TNF-a release after liver resection is still unclear. Stimulation
of p38 mitogen-activated protein (MAP) kinase has been reported
to contribute to the stabilization of TNF-a mRNA in macrophages
[35]. In addition, TNF-a augments itself in an autocrine fashion
through activation of the p38 MAP kinase-related intracellular
signal pathway [36]. EPO clearly activates the p38 signaling
pathway [37] and exerts its protective effect amongst others via
activation of p38 MAP kinase [38]. Thus, it might be supposed
that both the initially elevated TNF-a plasma level after liver
resection and the EPO application lead to an activation of p38
signaling pathway finally causing the unexpected surge of TNF-a.
The pro-apoptotic shift of the Bcl-xL/Bax ratio may result from
increased levels of TNF-a. In support of this view, culture
supernatants from activated Kupffer cells in a mouse tumor model
were able to change the balance between Bax and Bcl-2 in favor of
Bax [39]. Although TNF-a is thought to be an initial and
mandatory cytokine for liver regeneration [40], Tsutsumi et al.
Figure 5. PCNA-expression and BrdU-incorporation. Quantitative analysis and representative images of PCNA expressing hepatocytes (A, B
and C) and incorporation of BrdU (A, D and E) in animals at 24 h after pHx and daily administration of low dose of EPO (500 IU/kg bw iv; closed bars)
or physiologic saline solution (open bars). Fuchsin-red (B and C) and DAB-brown (D and E) positive hepatocytes are PCNA-expressing and BrdU-
incorporating cells, reflecting cells undergoing proliferation and DNA-synthesis. Note the marked reduction of these cells within the liver tissues of
the EPO-treated animals (C and E). Bars represent 50 mm. Means6SEM; unpaired Student’s t-test. * P,0.05 vs the saline-treated group.
doi:10.1371/journal.pone.0003924.g005
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improve liver function and facilitate liver regeneration after
extended hepatectomy [41]. Hepatocytes from TIMP3
2/2 mice,
which failed to control release of TNF-a, completed the cell cycle
in a model of liver regeneration, but then underwent cell death
owing to sustained activation of TNF-a [42]. Thus, it is reasonable
to assume that the overwhelming release of TNF-a in the present
study contributed to the impairment of liver regeneration.
Transgenic mice showing cerebal and systemic overexpression
of EPO revealed an impaired outcome in a model of focal brain
ischemia [43]. The authors have pointed out that chronic systemic
treatment with EPO may deteriorate outcome after stroke either
because of elevated hematocrit or other chronic effects [43]. We
observed a significant increase of hematocrit and RBC count over
the 5-day study period in the hepatectomized animals, which
received the high dose of EPO. It is reasonable to speculate that
this hematopoietic response with respect to pro-coagulant and pro-
thrombotic effects might have contributed to the increase of TNF-
a release and impaired liver regeneration. However, in vivo
fluorescence microscopic analysis of regenerating livers revealed
no significant decline of perfused sinusoids in EPO-treated animals
in comparison to controls at all studied timepoints after
hepatectomy (data not shown). Moreover, even the ten-fold lower
dose of EPO with negligible hematopoiesis significantly diminished
the regeneration capacity of the liver at the timepoint of maximal
DNA synthesis, i.e. at 24 h after pHx. Thus the harmful effect of
EPO in liver regeneration seems to be rather independent of its
hematopoietic action.
In conclusion, enhanced release of TNF-a following multiple
dosing of EPO after hepatectomy resulted in an increase of
apoptotic cell death and a delay of liver regeneration. Careful
consideration should therefore be made in repetitive pre- and post-
operative rHuEPO administration in the setting of liver resection
and transplantation.
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